- Home
- BDCI vs LYEL Comparison
BDCI vs LYEL Comparison
Compare BDCI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDCI | LYEL |
|---|---|---|
| Founded | 2023 | 2018 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.5M | 385.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BDCI | LYEL |
|---|---|---|
| Price | $10.04 | $16.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 62.1K | 51.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.96 | $0.40 |
| 52 Week High | $10.20 | $45.00 |
Technical Indicators
Market Signals| Indicator | BDCI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 34.50 |
| Support Level | $10.02 | $15.82 |
| Resistance Level | $10.05 | $19.02 |
| Average True Range (ATR) | 0.01 | 1.20 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 71.43 | 29.22 |
Price Performance
Historical ComparisonAbout BDCI BTC Development Corp. Class A Ordinary Shares
BTC Development Corp is a blank check company.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.